Longevity Peptide · Telomerase / Pineal

Epitalon: Telomerase-Activating Pineal Tetrapeptide

A UK-focused, evidence-based comparison of Epitalon and Dihexa — mechanism, benefits, dosing, side effects, legal status, and stacking.

Epitalon (also written Epithalon, Epithalone) is a synthetic four-amino-acid peptide developed in the 1990s by the laboratory of Vladimir Khavinson at the St Petersburg Institute of Bioregulation and Gerontology, building on Khavinson's earlier work on the bovine pineal-derived peptide Epithalamin. Sequence: Ala-Glu-Asp-Gly. It has been studied extensively in Russian gerontology research as a putative longevity and anti-ageing peptide based on its reported activation of telomerase and modulation of the pineal melatonin axis. Despite a substantial Russian literature including small clinical trials, Epitalon has not been registered as a medicine in any major Western market and remains an investigational peptide in the longevity research community.

What is Epitalon?

Epitalon is a synthetic tetrapeptide rationally derived from the larger porcine and bovine pineal peptide preparations (Epithalamin) developed by the Soviet-era Khavinson lab. It is sold as a lyophilised powder for reconstitution and injection (subcutaneous or intramuscular) or intranasal delivery. The compound is the most-studied of the Khavinson peptide series, which includes about 20 short peptides each targeting a specific tissue (Vesugen for vascular, Pinealon for brain, etc.) — all built on the Khavinson hypothesis that short peptides serve as gene-regulatory signals binding specific DNA sequences and triggering tissue-specific gene expression programmes. Around 50-80 published peer-reviewed papers exist on Epitalon, almost all from the Khavinson group or affiliated Russian institutions.

Chemistry: Ala-Glu-Asp-Gly · 4-mer · MW 390.35 g/mol
Origin: Khavinson laboratory, St Petersburg Institute of Bioregulation and Gerontology (Russia), 1990s
Primary route: Subcutaneous, intramuscular, or intranasal
Pharmacokinetics: Short plasma half-life (minutes) but downstream telomerase activation and pineal modulation reported to persist weeks after a 10-20 day course.
Class: Tetrapeptide · Telomerase activator

Mechanism of Action

Epitalon's proposed mechanism is activation of telomerase (the ribonucleoprotein enzyme that extends telomeres at chromosome ends) in somatic cells where telomerase is normally silenced. This has been demonstrated in vitro in human fibroblasts (Khavinson et al., 2003) and reported to extend cellular lifespan by 20-30% in cultured cells. The downstream effects include: modulation of pineal melatonin synthesis and circadian rhythm, particularly in aged animals where pineal function declines; normalisation of cortisol and HPA-axis function under chronic stress; reduction of age-related immune decline markers; and upregulation of various tissue-specific gene expression programmes consistent with the broader Khavinson peptide hypothesis. The Khavinson "telomerase activation" claim is the most-cited but also the most-contested element of the mechanism; independent Western replication is limited.

Proposed Benefits

Reported benefits across the Russian literature include: extension of mean and maximum lifespan in aged rodents (Anisimov et al., 2003, 2012), normalisation of circadian and sleep patterns in elderly subjects, improved immune markers, reduced age-related cancer incidence in tumour-prone mouse strains (a counter-intuitive but reported finding), modulation of glucose tolerance and lipid profile, and subjective improvements in sleep quality, energy, mood and skin appearance in human users. In the longevity research community Epitalon is frequently included in anti-ageing peptide stacks for its purported telomerase activation. Important caveat: the claim of mean lifespan extension in mammals is extraordinary and would represent a major biological finding if reproducible. Independent Western replication of the lifespan-extension claim is essentially absent.

Evidence Base

Approximately 50-80 published papers exist, the majority from the Khavinson laboratory. Key references: Khavinson et al. 2003 (telomerase activation in human fibroblasts); Anisimov et al. 2003 (lifespan extension in CBA mice); Khavinson and Anisimov 2009 (Russian summary review); Korkushko et al. 2006 (small human trial in elderly subjects reporting clinical improvements). The body of evidence has the same limitation as the broader Khavinson peptide series: concentration in one laboratory, limited independent replication, modest sample sizes, and methodological concerns about blinding and randomisation. The mechanism (telomerase activation) is a plausible and active area of research in general, but the specific evidence base for Epitalon as a clinically useful longevity intervention is preliminary by Western standards.

Dosage & Administration

No medically approved dose exists. Community protocols typically use 5-10 mg subcutaneously per day for 10-20 days as an annual or biannual course, mirroring the Russian clinical trial dosing. Intranasal protocols use a similar daily milligram amount over the same course duration. The course-based protocol (10-20 days, repeated annually) is distinctive among research peptides — most are dosed continuously or on shorter cycles. Reconstitute lyophilised powder with bacteriostatic water and refrigerate; reconstituted solution is stable 14-21 days. Subcutaneous injection in the abdomen is the most common route. Daily fractionation (e.g. 2.5 mg morning and evening) is sometimes preferred to a single daily injection.

This is a community-reported protocol summary, not a medical recommendation. There is no established human dose. Consult a qualified healthcare professional before using any research compound.

Side Effects & Risks

Epitalon has an unusually clean reported safety profile across the Russian literature and decades of self-experimentation use. Reported issues are rare and mild: occasional injection site reactions, very rare mild sleepiness or sedation (consistent with pineal/melatonin modulation), occasional vivid dreams. Theoretical concerns centre on the telomerase activation claim: telomerase is upregulated in 80-90% of human cancers, and exogenous telomerase activation has theoretical potential to promote tumour growth or accelerate progression of pre-existing malignancies. This concern has not been clinically demonstrated but the long-term safety of repeated annual courses in healthy adults is uncharacterised. Contraindications: active or recent cancer, family history of telomere-related cancers, pregnancy/breastfeeding, known peptide hypersensitivity.

UK Legal Status

UK: not a controlled substance, not licensed by MHRA, not scheduled under the Psychoactive Substances Act. Legal as a research chemical for laboratory use. WADA: Epitalon is not currently on the Prohibited List as of the 2026 update, though athletes should confirm with the current list. US: not FDA-approved; the FDA has cracked down on compounding pharmacy sales of Khavinson-series peptides in recent years. Russia: Epitalon is part of the registered Khavinson series of bioregulator peptides sold for human use under prescription, though regulatory status varies between products in the series.

Epitalon vs Dihexa

Epitalon and Dihexa are conceptually different categories of peptide. Epitalon is a longevity / anti-ageing peptide acting through purported telomerase activation and pineal modulation, with effects targeting cellular ageing markers and systemic ageing biology. Dihexa is a CNS-targeted synaptogenic peptide promoting structural plasticity in the brain via HGF/c-Met. They do not compete for the same use case. The two could in principle stack — Epitalon for systemic ageing biology, Dihexa for cognitive plasticity — though both have evidence-base limitations and combining novel research peptides increases the uncertainty of outcome. Of the two, Dihexa has the more defined and replicable mechanism; Epitalon has the more ambitious claimed effects but a weaker independent evidence base.

Stacking with Dihexa

Epitalon is the canonical centrepiece of "longevity peptide" stacks in the bio-hacker community, typically combined with other Khavinson series peptides (Pinealon, Vesugen, Cartalax, etc.) in annual or biannual course protocols. With Dihexa the rationale would be combining cellular-ageing intervention (Epitalon) with cognitive structural plasticity (Dihexa). No published interaction data exists. Epitalon is sometimes stacked with low-dose melatonin (the pineal axis they both modulate), NMN/NR (for NAD+ support), and resveratrol (for sirtuin pathway support) in broader longevity stacks. Cancer screening baseline is advisable before any long course of Epitalon given the theoretical telomerase concern.

Frequently Asked Questions

It has been reported to extend mean and maximum lifespan in aged rodents in the Anisimov 2003 and 2012 studies. These results have not been independently replicated outside the originating Russian lab group, which is a significant evidence limitation.

Reported safety across decades of Russian use is reassuring, but long-term human safety data in healthy adults using cyclic enhancement protocols is essentially absent. The theoretical telomerase / cancer concern has not been clinically demonstrated.

The Khavinson protocol uses 10-20 day courses repeated annually or biannually. The rationale is that bioregulator peptides trigger gene expression programmes that persist after the molecule clears, so continuous dosing is unnecessary and possibly counter-productive.

Oral bioavailability is essentially zero — the peptide is degraded by stomach acid and gut peptidases. Subcutaneous, intramuscular, and intranasal are the only viable routes.

Epitalon was not on the WADA Prohibited List as of the 2026 update, but athletes should confirm with the current list before competition.

Epithalamin is the original bovine pineal extract (a complex peptide preparation) developed by Khavinson in the 1970s-80s. Epitalon is the synthetic tetrapeptide rationally derived from the active fraction of Epithalamin.

The Bottom Line

Epitalon is the most-studied longevity peptide from the Khavinson Russian bioregulator series, with claimed effects on telomerase activity, pineal melatonin function, and mammalian lifespan that are intriguing but not independently replicated by Western groups. It occupies a conceptually distinct niche from Dihexa — systemic ageing biology versus cognitive structural plasticity — and the two are theoretically complementary in a broader longevity protocol. The cancer-acceleration theoretical concern from telomerase activation argues for cautious, course-based use only in users with no active malignancy and a clean diagnostic baseline.